burapitant
- Generic Name
- burapitant
SSR240600C Treatment in Women With Overactive Bladder
Phase 2
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 345
- Registration Number
- NCT00564226
- Locations
- 🇺🇸
Sanofi-Aventis Aministrative Office, Bridgewater, New Jersey, United States
🇵🇹Sanofi-Aventis Administrative Office, Porto Salvo, Portugal
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
Phase 2
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT00174798
- Locations
- 🇺🇸
Hudson Valley Urology Center, Kingston, New York, United States
🇺🇸Hudson Valley Urology, Poughkeepsie, New York, United States
🇺🇸Rockhill Medical Plaza, Kansas City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath